PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.26%
Revenue growth similar to META's 12.29%. Walter Schloss would see if both companies share industry tailwinds.
14.70%
Gross profit growth 1.25-1.5x META's 12.33%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
19.62%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
19.62%
Operating income growth 1.25-1.5x META's 16.44%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
20.45%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
23.08%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
15.38%
Diluted EPS growth 1.25-1.5x META's 11.04%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.23%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.76%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
0.20%
OCF growth under 50% of META's 6.39%. Michael Burry might suspect questionable revenue recognition or rising costs.
-1.16%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
2540.86%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
457.09%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
97.81%
3Y revenue/share CAGR 1.25-1.5x META's 77.04%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
538.94%
5Y OCF/share CAGR at 75-90% of META's 653.02%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
184.94%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
3163.51%
Net income/share CAGR 1.25-1.5x META's 2770.56%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
732.81%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
81.97%
Below 50% of META's 194.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
958.39%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
100.75%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.16%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.87%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
7.41%
Asset growth 1.25-1.5x META's 5.19%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
6.52%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-2.81%
Our R&D shrinks while META invests at 6.52%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
18.13%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.